De Ono
Board member
Pharmaceutical Sciences
Cell Centric
United Kingdom
Biography
Johann de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden. He is also the Director of The Drug Development Unit, overseeing the conduct of Phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. Additionally, he leads the Prostate Cancer Targeted Therapy Clinical Trials Team and the Cancer Biomarkers laboratory team. Johann de Bono graduated from the University of Glasgow medical school in 1989, graduating as a Member of the Royal College of Physicians (MRCP) in 1992. He was awarded a four-year Cancer Research Campaign Clinical Fellowship, which allowed him to pursue a PhD between 1993 and 1997. He trained in medical oncology, and was awarded an MSc (Cancer Sciences) from Glasgow University. The Royal College of Physicians and Surgeons of Glasgow then awarded him a travelling scholarship that allowed him to pursue further research on the challenges of clinical trial design at the SWOG statistical headquarters at the Fred Hutchinson Cancer Centre in Seattle, USA in 1999. Between 2000 and 2003 he then pursued further research developing novel anti-cancer drugs at the Institute for Drug Development within the University of Texas Health Science Centre at San Antonio. Johann de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden. He is also the Director of The Drug Development Unit, overseeing the conduct of Phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. Additionally, he leads the Prostate Cancer Targeted Therapy Clinical Trials Team and the Cancer Biomarkers laboratory team. Johann de Bono graduated from the University of Glasgow medical school in 1989, graduating as a Member of the Royal College of Physicians (MRCP) in 1992. He was awarded a four-year Cancer Research Campaign Clinical Fellowship, which allowed him to pursue a PhD between 1993 and 1997. He trained in medical oncology, and was awarded an MSc (Cancer Sciences) from Glasgow University. The Royal College of Physicians and Surgeons of Glasgow then awarded him a travelling scholarship that allowed him to pursue further research on the challenges of clinical trial design at the SWOG statistical headquarters at the Fred Hutchinson Cancer Centre in Seattle, USA in 1999. Between 2000 and 2003 he then pursued further research developing novel anti-cancer drugs at the Institute for Drug Development within the University of Texas Health Science Centre at San Antonio.
Research Interest
Pharmaceutical Sciences